First Time Loading...

Wuhan Easy Diagnosis Biomedicine Co Ltd
SZSE:002932

Watchlist Manager
Wuhan Easy Diagnosis Biomedicine Co Ltd Logo
Wuhan Easy Diagnosis Biomedicine Co Ltd
SZSE:002932
Watchlist
Price: 19.92 CNY 0.5% Market Closed
Updated: May 18, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

7.4B
-4%
Assets
Growth Rates:
1 Year
-20%
3 Years
+418%
5 Years
+1 097%
7 Years
-
10 Years
-
1.4B
-16%
Liabilities
Growth Rates:
1 Year
-49%
3 Years
+319%
5 Years
+4 592%
7 Years
-
10 Years
-
6B
-0.9%
Equity
Growth Rates:
1 Year
-7%
3 Years
+447%
5 Years
+924%
7 Years
-
10 Years
-

Balance Sheet Decomposition
Wuhan Easy Diagnosis Biomedicine Co Ltd

7.4B
Assets
1.4B
Liabilities
7.4B
Assets
1.4B
Liabilities
Current Assets 2.7B
Cash & Short-Term Investments 1.2B
Receivables 1.3B
Other Current Assets 185.3m
Non-Current Assets 4.6B
Long-Term Investments 3.8B
PP&E 547.1m
Intangibles 17.7m
Other Non-Current Assets 225m
Current Liabilities 1B
Accounts Payable 681.6m
Accrued Liabilities 159.2m
Short-Term Debt 83.5m
Other Current Liabilities 95.1m
Non-Current Liabilities 341.3m
Long-Term Debt 18.3m
Other Non-Current Liabilities 323.1m

Balance Sheet
Wuhan Easy Diagnosis Biomedicine Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
11
97
89
125
268
171
669
1 190
2 352
1 016
Cash
0
0
0
0
0
0
0
1 190
2 352
1 016
Cash Equivalents
11
97
89
125
268
170
669
0
0
0
Short-Term Investments
22
0
25
0
160
200
200
700
2 023
225
Total Receivables
6
4
10
22
42
46
191
752
2 754
1 324
Accounts Receivables
3
4
7
17
29
32
181
739
2 560
1 209
Other Receivables
3
0
3
5
13
14
10
14
194
115
Inventory
8
9
9
15
20
39
118
285
258
129
Other Current Assets
1
7
12
6
16
16
41
73
91
57
Total Current Assets
48
118
145
167
506
472
1 218
3 000
7 682
2 750
PP&E Net
10
12
47
70
90
97
136
252
538
547
PP&E Gross
10
12
47
70
90
97
136
252
538
547
Accumulated Depreciation
1
2
6
15
28
44
60
83
281
386
Intangible Assets
3
3
3
19
18
17
17
17
17
18
Long-Term Investments
0
0
0
0
0
30
46
61
767
3 847
Other Long-Term Assets
0
1
2
1
4
22
9
88
191
225
Total Assets
61
N/A
134
+120%
197
+47%
257
+30%
617
+141%
638
+3%
1 427
+123%
3 417
+140%
9 195
+169%
7 387
-20%
Liabilities
Accounts Payable
4
3
2
4
4
7
31
174
1 294
682
Accrued Liabilities
3
4
7
7
6
7
32
87
379
159
Short-Term Debt
0
5
7
0
8
1
143
35
184
83
Current Portion of Long-Term Debt
0
0
0
0
0
0
0
4
18
7
Other Current Liabilities
5
6
6
1
3
5
104
247
490
88
Total Current Liabilities
11
18
21
12
22
20
309
546
2 365
1 019
Long-Term Debt
0
0
0
0
0
0
0
11
21
18
Deferred Income Tax
0
1
1
1
3
3
2
4
31
40
Minority Interest
0
0
0
2
4
6
13
61
272
266
Other Liabilities
0
0
0
0
0
0
0
6
6
17
Total Liabilities
11
N/A
19
+63%
22
+19%
16
-28%
29
+81%
29
-1%
325
+1 032%
628
+93%
2 695
+329%
1 361
-50%
Equity
Common Stock
7
50
50
50
67
67
69
105
156
233
Retained Earnings
23
38
98
163
198
220
682
1 812
5 472
4 973
Additional Paid In Capital
20
27
27
27
324
324
400
904
888
820
Treasury Stock
0
0
0
0
0
0
49
33
16
0
Total Equity
50
N/A
115
+133%
175
+52%
241
+37%
588
+144%
610
+4%
1 102
+81%
2 789
+153%
6 500
+133%
6 026
-7%
Total Liabilities & Equity
61
N/A
134
+120%
197
+47%
257
+30%
617
+141%
638
+3%
1 427
+123%
3 417
+140%
9 195
+169%
7 387
-20%
Shares Outstanding
Common Shares Outstanding
7
50
50
50
67
67
67
225
228
231

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 138,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.